These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 5294603)

  • 1. Pyridinolcarbamate, bradykinin antagonist, in patients suffering from arteriosclerosis obliterans and thromboangiitis obliterans (Buerger's disease); a preliminary report on the treatment of human atherosclerosis.
    Shimamoto T; Atsumi T
    Jpn Heart J; 1965 Sep; 6(5):407-15. PubMed ID: 5294603
    [No Abstract]   [Full Text] [Related]  

  • 2. [On the treatment of "intermittent claudication" in chronic peripheral obliterating arteriopathies of the lower extremities caused by arteriosclerosis and Buerger's disease].
    Seghezzi R; Pedroni G; Borri P
    Chir Ital; 1967; 19():Suppl 2:222+. PubMed ID: 5190600
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of pyridinolcarbamate on blood coagulation and thrombolysis in patients with arteriosclerosis obliterans].
    Hess H; Goossens N; Keil-Kuri E; Zollner R; Meyer A
    Vasa; 1972; 1(3):206-11. PubMed ID: 5076123
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of occlusive diseases of the arteries in the limbs with pyridinol-carbamate.
    Matsumoto K; Sato K; Tanaka S
    Jpn Heart J; 1966 Jan; 7(1):87-93. PubMed ID: 5295647
    [No Abstract]   [Full Text] [Related]  

  • 5. Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
    Walton KW; Craig GM; Prior P; Waterhouse JA; Skilton J
    Br Heart J; 1973 Feb; 35(2):211-9. PubMed ID: 4570447
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of surheme on improved blood flow in limbs].
    Wesolowski J; Hubl S; Godziemba-Maliszewska E
    Wiad Lek; 1972 Jul; 25(14):1297-300. PubMed ID: 5054661
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of thromboangiitis obliterans (Buerger's disease) with high-potency vasodilators.
    Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Blanco-Sánchez G; Rodríguez-Mateos ME; Linares-Barrios M
    Dermatol Ther; 2015; 28(3):135-9. PubMed ID: 25649782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic properties of xanthine nicotinate in the treatment of obliterating arteriopathies].
    Tardito E; Azzolini A; De Cristofaro A; Papacharalambus D
    Minerva Cardioangiol; 1972; 20(7):369-89. PubMed ID: 5050745
    [No Abstract]   [Full Text] [Related]  

  • 9. [Mydocalm administered in electrophoresis].
    Chmielewski F
    Pol Tyg Lek; 1971 Jul; 26(30):1170-2. PubMed ID: 5092988
    [No Abstract]   [Full Text] [Related]  

  • 10. [The vasoactivogram in the treatment of peripheral arteriopathies].
    Romeo S; Spinella G; Sciacchitanto D
    Angiologia; 1975; 27(1):7-25. PubMed ID: 1111377
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 12. THROMBOANGIITIS OBLITERANS (BUERGER'S DISEASE).
    ABRAMSON DI
    Heart Bull; 1964; 13():48-51. PubMed ID: 14146982
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography].
    Motomiya T
    Nihon Naika Gakkai Zasshi; 1970 Feb; 59(2):117-25. PubMed ID: 4910199
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical tests using pyridinol carbamate on the arterial circulation and blood coagulation in patients with arteriosclerosis obliterans].
    De Soldati L; Castro CM; Grilli H; Reussi J
    Prensa Med Argent; 1969 May; 56(12):546-53. PubMed ID: 5343928
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful Percutaneous Transcatheter Angioplasty of Radial Artery in Thromboangiitis Obliterans (Buerger's Disease).
    Taniguchi T; Higuchi T; Tazaki J; Saito N; Kimura T
    JACC Cardiovasc Interv; 2017 Nov; 10(22):e205-e206. PubMed ID: 28917511
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of atherosclerosis by pyridinolcarbamate. Review of the history of the introduction of pyridinolcarbamate and its clinical results].
    Shimamoto T
    Rev Atheroscler (Paris); 1968; 10(3):67-84. PubMed ID: 5746502
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical pharmacologic evaluation of the antiatherosclerotic agent, pyridinolcarbamate. A double-blind crossover trial in the treatment of atherosclerosis obliterans.
    Shimamoto T; Atsumi T; Yamashita S; Motomiya T; Isokane N; Ishioka T; Sakuma A
    Am Heart J; 1970 Jan; 79(1):5-19. PubMed ID: 4903137
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current news in the pharmacological and surgical treatment of chronic, peripheral, obliterating arterial diseases of the lower limbs].
    Argenteri A; Bagliani A; Borri P; Ugolini U
    Clin Ter; 1974 Aug; 70(3):281-91. PubMed ID: 4423739
    [No Abstract]   [Full Text] [Related]  

  • 19. Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography.
    Motomiya T; Atsumi T; Isokane N; Yamashita S; Sano T
    Jpn Heart J; 1970 Sep; 11(5):433-49. PubMed ID: 4921577
    [No Abstract]   [Full Text] [Related]  

  • 20. [Anticardiolipin antibodies in patients with Buerger's disease].
    Cnotliwy M; Gutowski P; Szumiłowicz H; Kucharska E; Jastrzebska M; Ostanek L
    Wiad Lek; 1999; 52(7-8):332-6. PubMed ID: 10540577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.